Trial · NCT05231629
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
NCT05231629, Phase 2, Active not recruiting, University of Alabama at Birmingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sequential Therapy in Multiple Myeloma Guided by MRD Assessments. Trials, record NCT05231629. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05231629
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
- NCT number
- NCT05231629
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 300 participants, estimated
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Multiple Myeloma
- Interventions
Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
- First posted
- 2022-02-09
- Last updated
- 2026-09-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Depth of response obtained with 6 cycles of Dara-VRd | 6 months | For the primary objective "for all patients" to describe the depth of response obtained with 6 cycles of Dara-VRd and the corresponding endpoint of MRD negativity at end of induction all patients with MRD evaluable |
| Primary | Sustained MRD negativity | 18 months | MRD \<10-5 assessed before and after 13 cycles of maintenance |
| Secondary | Progression-free survival | 60 months | Occurrence of disease progression or death |
| Secondary | Overall Survival | 60 months | Occurrence of death regardless of cause |
| Secondary | Cumulative incidence of MRD resurgence or progression | 60 months | Occurrence of MRD \>= 10-5 or progression for patients starting observation with MRD surveillance (MRD-SURE) after achieving sustained MRD negativity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05231629
GET https://conductscience.org/api/trials/v1/NCT05231629/registered